The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Open accessAbstract
Cognitive dysfunction is one of the most typical characteristics in various neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (advanced stage). Although several mechanisms like neuronal apoptosis and inflammatory responses have been recognized to be involved in the pathogenesis of cognitive dysfunction in these diseases, recent studies on neurodegeneration and cognitive dysfunction have demonstrated a significant impact of receptor modulation on cognitive changes. The pathological alterations in various receptors appear to contribute to cognitive impairment and/or deterioration with correlation to diversified mechanisms. This article recapitulates the present understandings and concepts underlying the modulation of different receptors in human beings and various experimental models of Alzheimer’s disease and Parkinson’s disease as well as a conceptual update on the underlying mechanisms. Specific roles of serotonin, adrenaline, acetylcholine, dopamine receptors, and N-methyl-D-aspartate receptors in Alzheimer’s disease and Parkinson’s disease will be interactively discussed. Complex mechanisms involved in their signaling pathways in the cognitive dysfunction associated with the neurodegenerative diseases will also be addressed. Substantial evidence has suggested that those receptors are crucial neuroregulators contributing to cognitive pathology and complicated correlations exist between those receptors and the expression of cognitive capacities. The pathological alterations in the receptors would, therefore, contribute to cognitive impairments and/or deterioration in Alzheimer’s disease and Parkinson’s disease. Future research may shed light on new clues for the treatment of cognitive dysfunction in neurodegenerative diseases by targeting specific alterations in these receptors and their signal transduction pathways in the frontal-striatal, fronto–striato–thalamic, and mesolimbic circuitries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 2×
“confirmed enhanced endocytosis of NMDA receptors by Ab in AD (Snyder et al., 2005).”
Dopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131 · cited 1×
“Constituting the major part of non-motor dysfunction, cognitive deficits in advanced PD patients have recently drawn wider attention (Nieoullon, 2002).”
BackgroundNichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 9×
“Recent studies have demonstrated significant roles of D1 and D2 receptors in modulating synaptic plasticity and mediating cognitive dysfunction via cAMP/PKA signaling cascades, DARPP-32, and CREB modulation (Chang and Berg, 2001; Hu et al., 2002).”
BackgroundInfluentialNMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“Ab oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism, which can be blocked by memantine, an NMDA receptor antagonist (De Felice et al., 2007).”
BackgroundNeuronal nicotinic receptors in the human brain
Paterson, D., & Nordberg, A. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00045-3 · Cited by 782
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 666
Valjent, E., Pascoli, V., Svenningsson, P., Paul, S., Enslen, H., Corvol, J.-C., Stipanovich, A., Caboche, J., Lombroso, P. J., Nairn, A. C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408305102 · Cited by 614
Impey, S., Obrietan, K., & Storm, D. R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80747-3 · Cited by 613
Temporal processing in the basal ganglia.
Harrington, D. L., Haaland, K. Y., & Hermanowitz, N. (1998) · Neuropsychology · doi:10.1037//0894-4105.12.1.3 · Cited by 483
Hernández-López, S., Tkatch, T., Perez-Garci, E., Galarraga, E., Bargas, J., Hamm, H., & Surmeier, D. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-08987.2000 · Cited by 443 · cited 2×
“The simultaneous activation of the dopamine D2 receptor suppresses transmembrane Ca currents, activated phospholipase C (PLC) and the calcium-dependent phosphatase calcineurin (Hernandez-Lopez et al., 2000).”
BackgroundTiming and Location of Nicotinic Activity Enhances or Depresses Hippocampal Synaptic Plasticity
Ji, D., Lape, R., & Dani, J. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00332-4 · Cited by 419
The Akt–GSK-3 signaling cascade in the actions of dopamine
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.006 · Cited by 419
Ruat, M., Traiffort, E., Arrang, J. M., Tardivellacombe, J., Diaz, J., Leurs, R., & Schwartz, J. C. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1619 · Cited by 412
5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome
HOYER, D., & MARTIN, G. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00036-1 · Cited by 410
Gerfen, C. R., Miyachi, S., Paletzki, R., & Brown, P. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-12-05042.2002 · Cited by 373
The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease
Miranda, S., Opazo, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., & Inestrosa, N. C. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00015-0 · Cited by 369
Piggott, M. A., Marshall, E. F., Thomas, N., Lloyd, S., Court, J. A., Jaros, E., Burn, D., Johnson, M., Perry, R. H., McKeith, I. G., et al. (1999) · Brain · doi:10.1093/brain/122.8.1449 · Cited by 330
Regulation of Akt Signaling by D2and D3Dopamine Receptors In Vivo
Beaulieu, J.-M., Tirotta, E., Sotnikova, T. D., Masri, B., Salahpour, A., Gainetdinov, R. R., Borrelli, E., & Caron, M. G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5074-06.2007 · Cited by 269
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 263
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease
Sawamoto, N., Piccini, P., Hotton, G., Pavese, N., Thielemans, K., & Brooks, D. J. (2008) · Brain · doi:10.1093/brain/awn054 · Cited by 263
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
Upton, N., Chuang, T. T., Hunter, A. J., & Virley, D. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.008 · Cited by 255
Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., & Raskind, M. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4265-05.2006 · Cited by 248
Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1850-08.2008 · Cited by 247
NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243
Antonini, A. (1997) · Brain · doi:10.1093/brain/120.12.2187 · Cited by 241
NMDA Receptor-Mediated K + Efflux and Neuronal Apoptosis
Yu, S. P., Yeh, C.-H., Strasser, U., Tian, M., & Choi, D. W. (1999) · Science · doi:10.1126/science.284.5412.336 · Cited by 238
Rationale for and use of NMDA receptor antagonists in Parkinson's disease
Hallett, P. J., & Standaert, D. G. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.001 · Cited by 237
Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system
Shen, J.-X., & Yakel, J. L. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.64 · Cited by 236
Hirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.049 · Cited by 234
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233
5-HT6 receptors: a novel target for cognitive enhancement
Mitchell, E. S., & Neumaier, J. F. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.001 · Cited by 233
5-HT1A receptor-regulated signal transduction pathways in brain
Polter, A. M., & Li, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.019 · Cited by 225
Hallett, P. J., Spoelgen, R., Hyman, B. T., Standaert, D. G., & Dunah, A. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0792-06.2006 · Cited by 225
Kurup, P., Zhang, Y., Xu, J., Venkitaramani, D. V., Haroutunian, V., Greengard, P., Nairn, A. C., & Lombroso, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0157-10.2010 · Cited by 224
Mehta, M. A., Sahakian, B. J., McKenna, P. J., & Robbins, T. W. (1999) · Psychopharmacology · doi:10.1007/s002130051102 · Cited by 223 · cited 2×
“likely involved in the frontostriatal pathway (Mehta et al., 1999).”
BackgroundSchechter, L. E., Lin, Q., Smith, D. L., Zhang, G., Shan, Q., Platt, B., Brandt, M. R., Dawson, L. A., Cole, D., Bernotas, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301503 · Cited by 222
Pascual, M., Baliño, P., Alfonso-Loeches, S., Aragón, C. M. G., & Guerri, C. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.02.012 · Cited by 213
Antonini, A., Schwarz, J., Oertel, W. H., Pogarell, O., & Leenders, K. L. (1997) · Movement Disorders · doi:10.1002/mds.870120107 · Cited by 208
Hernandez, C. M., Kayed, R., Zheng, H., Sweatt, J. D., & Dineley, K. T. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5038-09.2010 · Cited by 204 · cited 1×
“In an early AD mouse model, a7 nAChRs also provided neuroprotection through the maintenance of the septo-hippocampal cholinergic phenotype, the preservation of hippocampal integrity, and decreasing the Ab accumulation and oligomerization (Hernandez et al., 2010).”
BackgroundGulyás, B., Pavlova, E., Kása, P., Gulya, K., Bakota, L., Várszegi, S., Keller, É., Horváth, M. C., Nag, S., Hermecz, I., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.013 · Cited by 202
Dziewczapolski, G., Glogowski, C. M., Masliah, E., & Heinemann, S. F. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6159-08.2009 · Cited by 198
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease
Rinne, J. O., Myllykyla¨, T., Lo¨nnberg, P., & Marjama¨ki, P. (1991) · Brain Research · doi:10.1016/0006-8993(91)90588-m · Cited by 195
Fortin, D. A., Davare, M. A., Srivastava, T., Brady, J. D., Nygaard, S., Derkach, V. A., & Soderling, T. R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1746-10.2010 · Cited by 186
Otani, S., Auclair, N., Desce, J.-M., Roisin, M.-P., & Crépel, F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-22-09788.1999 · Cited by 185
Bitner, R. S., Bunnelle, W. H., Anderson, D. J., Briggs, C. A., Buccafusco, J., Curzon, P., Decker, M. W., Frost, J. M., Gronlien, J. H., Gubbins, E., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2444-07.2007 · Cited by 184
Self-citationChang, K. T., & Berg, D. K. (2001) · Neuron · doi:10.1016/s0896-6273(01)00516-5 · Cited by 177
Role of the ERK pathway in psychostimulant-induced locomotor sensitization
Valjent, E., Corvol, J.-C., Trzaskos, J. M., Girault, J.-A., & Hervé, D. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-20 · Cited by 175
Antonini, A., Vontobel, P., Psylla, M., Gunther, I., Maguire, P. R., Missimer, J., & Leenders, K. L. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540360061017 · Cited by 174
Lai, M. K. P., Tsang, S. W. Y., Francis, P. T., Esiri, M. M., Keene, J., Hope, T., & Chen, C. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02554-x · Cited by 173
Blin, J., Baron, J. C., Dubois, B., Crouzel, C., Fiorelli, M., Attar-Lévy, D., Pillon, B., Fournier, D., Vidailhet, M., & Agid, Y. (1993) · Brain · doi:10.1093/brain/116.3.497 · Cited by 172
Insights into the Role of Dopamine Receptor Systems in Learning and Memory
El-Ghundi, M., O'Dowd, B. F., & George, S. R. (2007) · Reviews in the Neurosciences · doi:10.1515/revneuro.2007.18.1.37 · Cited by 170
Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease
Péron, J., Vicente, S., Leray, E., Drapier, S., Drapier, D., Cohen, R., Biseul, I., Rouaud, T., Le Jeune, F., Sauleau, P., et al. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.09.008 · Cited by 167
Decker, H., Jürgensen, S., Adrover, M. F., Brito‐Moreira, J., Bomfim, T. R., Klein, W. L., Epstein, A. L., De Felice, F. G., Jerusalinsky, D., & Ferreira, S. T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07058.x · Cited by 166
Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease
Kemppainen, N., Laine, M., Laakso, M. P., Kaasinen, V., Någren, K., Vahlberg, T., Kurki, T., & Rinne, J. O. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02716.x · Cited by 165
GUBELLINI, P., PISANI, A., CENTONZE, D., BERNARDI, G., & CALABRESI, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.005 · Cited by 165
Kalaria, R. N., Andorn, A. C., Tabaton, M., Whitehouse, P. J., Harik, S. I., & Unnerstall, J. R. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09242.x · Cited by 163
Meyer, P. M., Strecker, K., Kendziorra, K., Becker, G., Hesse, S., Woelpl, D., Hensel, A., Patt, M., Sorger, D., Wegner, F., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.106 · Cited by 158
Mishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156
Poulin, B., Butcher, A. J., McWilliams, P., Bourgognon, J.-M., Pawlak, R., Kong, K. C., Bottrill, A. R., Mistry, S. C., Wess, J., Rosethorne, E. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914801107 · Cited by 156
García-Alloza, M., Hirst, W. D., Chen, C., Lasheras, B., Francis, P. T., & Ramírez, M. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300330 · Cited by 154
Miwa, J. M., Stevens, T. R., King, S. L., Caldarone, B. J., Ibanez-Tallon, I., Xiao, C., Fitzsimonds, R. M., Pavlides, C., Lester, H. A., Picciotto, M. R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.025 · Cited by 154
Mattila, P. M., Röyttä, M., Lönnberg, P., Marjamäki, P., Helenius, H. Y. M., & Rinne, J. O. (2001) · Acta Neuropathologica · doi:10.1007/s004010100372 · Cited by 150
Endogenous dopamine release after pharmacological challenges in Parkinson's disease
Piccini, P. P., Pavese, N., & Brooks, D. J. (2003) · Annals of Neurology · doi:10.1002/ana.10526 · Cited by 150
Cholinergic Receptors in Cognitive Disorders
Perry, E. K., Perry, R. H., Smith, C. J., Purohit, D. P., Bonham, J. R., Dick, D. J., Candy, J., Edwardson, J. A., & FAIRBAIRN, A. F. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037240 · Cited by 149
Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147
Stein, J. L., Hua, X., Morra, J. H., Lee, S., Hibar, D. P., Ho, A. J., Leow, A. D., Toga, A. W., Sul, J. H., Kang, H. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.068 · Cited by 145 · cited 1×
“One stereotaxic and genome-wide study confirmed that one SNP, rs10845840, which encodes the NMDA receptor NR2B subunit, is associated with temporal lobe volume and has proven to be a more informative phenotype than hippocampal volumes in AD (Stein et al., 2010).”
BackgroundHarré, E. ‐., Galic, M. A., Mouihate, A., Noorbakhsh, F., & Pittman, Q. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06031.x · Cited by 145
What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley, M. J., & Jenner, P. G. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.001 · Cited by 137
Politis, M., Piccini, P. P., Pavese, N., Koh, S., & Brooks, D. J. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.07.021 · Cited by 135
Inhibitory Effect of Hippocampal 5-HT1A Receptors on Human Explicit Memory
Yasuno, F., Suhara, T., Nakayama, T., Ichimiya, T., Okubo, Y., Takano, A., Ando, T., Inoue, M., Maeda, J., & Suzuki, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.334 · Cited by 135
Acetylcholine receptors in dementia and mild cognitive impairment
Sabri, O., Kendziorra, K., Wolf, H., Gertz, H., & Brust, P. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0701-1 · Cited by 134
Paradoxical Striatal Cellular Signaling Responses to Psychostimulants in Hyperactive Mice
Beaulieu, J., Sotnikova, T. D., Gainetdinov, R. R., & Caron, M. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606062200 · Cited by 130
Reduced 5-HT2A receptor binding in patients with mild cognitive impairment
Hasselbalch, S. G., Madsen, K., Svarer, C., Pinborg, L. H., Holm, S., Paulson, O. B., Waldemar, G., & Knudsen, G. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.011 · Cited by 129
Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease–Like Pathology and Cognitive Decline
Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto‐Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & LaFerla, F. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.041 · Cited by 127
Lai, M. K. P., Tsang, S. W., Alder, J. T., Keene, J., Hope, T., Esiri, M. M., Francis, P. T., & Chen, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2077-2 · Cited by 125
Hu, M., Liu, Q.-S., Chang, K. T., & Berg, D. K. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1202 · Cited by 119
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease
Kaasinen, V., Någren, K., Hietala, J. A., Oikonen, V., Vilkman, H., Farde, L., Halldin, C., & Rinne, J. O. (2000) · Neurology · doi:10.1212/wnl.54.7.1482 · Cited by 118
α7 Nicotinic Receptor Up-regulation in Cholinergic Basal Forebrain Neurons in Alzheimer Disease
Counts, S., He, B., Che, S., Ikonomović, M. D., DeKosky, S. T., Ginsberg, S. D., & Mufson, E. J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.12.1771 · Cited by 118
Cropley, V., Fujita, M., Bara‐Jimenez, W., Brown, A. K., Zhang, X., Sangare, J., Herscovitch, P., Pike, V. W., Hallett, M., Nathan, P. J., et al. (2008) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2007.11.003 · Cited by 117
Differential expression of N ‐methyl‐ d ‐aspartate receptor NR2 isoforms in Alzheimer's disease
Hynd, M. R., Scott, H. L., & Dodd, P. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02548.x · Cited by 116
Pralong, É., Magistretti, P., & Stoop, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00017-5 · Cited by 116
Guetg, N., Aziz, S. A., Holbro, N., Tureček, R., Rose, T., Seddik, R., Gassmann, M., Moes, S., Jenoe, P., Oertner, T. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000909107 · Cited by 113
Boileau, I., Guttman, M., Rusjan, P., Adams, J. R., Houle, S., Tong, J., Hornykiewicz, O., Furukawa, Y., Wilson, A. A., Kapur, S., et al. (2009) · Brain · doi:10.1093/brain/awn337 · Cited by 112
Bi, H., & Sze, C. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00087-4 · Cited by 111
Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease
Gong, Y., Lippa, C. F., Zhu, J., Lin, Q., & Rosso, A. L. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.056 · Cited by 109
Roncarati, R., Scali, C., Comery, T. A., Grauer, S. M., Aschmi, S., Bothmann, H., Jow, B., Kowal, D. M., Gianfriddo, M., Kelley, C., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.150094 · Cited by 107
Tsang, S. W. Y., Lai, M. K. P., Kirvell, S. L., Francis, P. T., Esiri, M. M., Hope, T., Chen, C., & Wong, P. T. ‐. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.010 · Cited by 106
PEREZGARCIA, G., & Meneses, A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.05.005 · Cited by 104
Adrenergic receptors in Parkinson's disease
Cash, R., Ruberg, M., Raisman‐Vozari, R., & Agid, Y. (1984) · Brain Research · doi:10.1016/0006-8993(84)90117-3 · Cited by 104
Russo‐Neustadt, A. A., & Cotman, C. W. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-14-05573.1997 · Cited by 99
Nair, V. D., & Sealfon, S. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303364200 · Cited by 98
Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease
Reeves, S., Brown, R., Howard, R., & Grasby, P. (2009) · Neurology · doi:10.1212/01.wnl.0000341932.21961.f3 · Cited by 98
Johnson, P. L., & Shekhar, A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0408-06.2006 · Cited by 97
Postmortem serotoninergic correlates of cognitive decline in Alzheimer??s disease
Lai, M. K. P., Tsang, S. W. Y., Francis, P. T., Keene, J., Hope, T., Esiri, M. M., Spence, I., & Chen, C. (2002) · Neuroreport · doi:10.1097/00001756-200207020-00021 · Cited by 96
Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions
Wüllner, U., Testa, C. M., Catania, M. V., Young, A. B., & Penney, J. B. (1994) · Brain Research · doi:10.1016/0006-8993(94)91642-x · Cited by 96
West, P. J., Marcy, V. R., Marino, M. J., & Schaffhauser, H. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.061 · Cited by 95
Sun, H., Zhang, J., Zhang, L., Liu, H., Zhu, H., & Yang, Y. (2010) · Current Neurovascular Research · doi:10.2174/156720210793180819 · Cited by 94
Yan, J., Xu, Y., Zhu, C., Zhang, L., Wu, A., Yang, Y., Xiong, Z., Deng, C., Huang, X., Yenari, M. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020945 · Cited by 94
Self-citationLateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease
Cheesman, A. L., Barker, R. A., Lewis, S. J. G., Robbins, T. W., Owen, A. M., & Brooks, D. J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.055079 · Cited by 93
Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies
Nagano‐Saito, A., Kato, T., Arahata, Y., Washimi, Y., Nakamura, A., Abe, Y., Yamada, T., Iwai, K., Hatano, K., Kawasumi, Y., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.01.030 · Cited by 90
da Costa, A. L. C., Peppe, A., Dell’Agnello, G., Caltagirone, C., & Carlesimo, G. A. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.01.039 · Cited by 90
Nicotinic Acetylcholine Receptors in Alzheimer's Disease
Wevers, A., & Schröder, H. (1999) · Journal of Alzheimer s Disease · doi:10.3233/jad-1999-14-503 · Cited by 89
Reeves, S., Grasby, P. M., Howard, R. J., Bantick, R. A., Asselin, M., & Mehta, M. A. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.05.034 · Cited by 88
Tanaka, Y. R., Meguro, K., Yamaguchi, S., Ishii, H., Watanuki, S., Funaki, Y., Yamaguchi, K., Yamadori, A., Iwata, R., & Itoh, M. (2003) · Annals of Nuclear Medicine · doi:10.1007/bf03006670 · Cited by 86
Belujon, P., Bézard, E., Taupignon, A., Bioulac, B. H., & Benazzouz, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2583-07.2007 · Cited by 82
Ułas, J., Brunner, L. C., Geddes, J. W., Choe, W. S., & Cotman, C. W. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90075-d · Cited by 82
Turner, T. J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1559-04.2004 · Cited by 81
5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment
Rossé, G., & Schaffhauser, H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411036 · Cited by 80
Marcos, B., Chuang, T. T., Gil-Bea, F. J., & Ramírez, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.281 · Cited by 79
Pizzolato, G., Chierichetti, F., Fabbri, M., Cagnin, A., Dam, M., Ferlin, G., & Battistin, L. (1996) · Neurology · doi:10.1212/wnl.47.4.1065 · Cited by 77
Wang, Q., Zengin, A., Deng, C., Li, Y., Newell, K. A., Yang, G., Lü, Y., Wilder-Smith, E. P., Zhao, H., & Huang, X. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.016 · Cited by 76
Self-citationRieckmann, A., Karlsson, S., Karlsson, P., Brehmer, Y., Fischer, H., Farde, L., Nyberg, L. H., & Bäckman, L. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq266 · Cited by 74
Shimohama, S., Taniguchi, T., Fujiwara, M., & Kameyama, M. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb00753.x · Cited by 74
PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD
Kemppainen, N. M., Ruottinen, H., Någren, K., & Rinne, J. O. (2000) · Neurology · doi:10.1212/wnl.55.2.205 · Cited by 70
Truchot, L., Costes, N., Zimmer, L., Laurent, B., Bars, D. L., Thomas-Antérion, C., Mercier, B., Hermier, M., Vighetto, A., & Krolak‐Salmon, P. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.01.030 · Cited by 69
Dopamine, hypertension and obesity
Contreras, F., Fouillioux, C., Bolívar, A., Simonovis, N., Hernández-Hernández, R., Armas-Hernández, M. J., & Velasco, M. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001334 · Cited by 68
Changes in β‐Adrenergic Receptor Subtypes in Alzheimer‐Type Dementia
Shimohama, S., Taniguchi, T., Fujiwara, M., & Kameyama, M. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb05649.x · Cited by 68
Neuronal nicotinic acetylcholine receptor–cholesterol crosstalk in Alzheimer's disease
Barrantes, F. J., Borroni, V., & Vallés, S. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.11.036 · Cited by 67
Janssen, W. G. M., Vissavajjhala, P., Andrews, G., Moran, T. M., Hof, P. R., & Morrison, J. H. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.020 · Cited by 66
Astrocytic β2-adrenergic receptors: From physiology to pathology
Laureys, G., Clinckers, R., Gerlo, S., Spooren, A., Wilczak, N., Kooijman, R., Smolders, I. J., Michotte, Y. M., & Keyser, J. D. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.011 · Cited by 65
5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
Meneses, A., & Hong, E. (1999) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1998.3866 · Cited by 62
Extrastriatal dopamine D 2 receptors in Parkinson's disease: a longitudinal study
Kaasinen, V., Aalto, S., N�gren, K., Hietala, J. A., Sonninen, P. H., & Rinne, J. O. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0816-x · Cited by 61
Proctor, D. T., Coulson, E. J., & Dodd, P. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.02.002 · Cited by 60
Ellis, J. R., Villemagne, V. L., Nathan, P. J., Mulligan, R. S., Gong, S., Chan, J. G., Sachinidis, J. I., O'Keefe, G., Pathmaraj, K., Wesnes, K. A., et al. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.05.006 · Cited by 60
Polymorphisms at the β2-adrenergic receptor gene influence Alzheimer's disease susceptibility
Yu, J., Tan, L., Ou, J.-R., Zhu, J., Liu, K., Song, J., & Sun, Y. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.019 · Cited by 59
Kalaria, R. N., & Andorn, A. C. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90051-k · Cited by 59
de Bartolomeis, A., Fiore, G., & Iasevoli, F. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414538 · Cited by 58
Lilja, A. M., Porras, O., Storelli, E., Nordberg, A., & Marutle, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101242 · Cited by 57 · cited 1×
“Ab oligomers may modulate calcium homeostasis, LTP and synaptic plasticity by binding to nAChRs, and stimulating downstream signaling pathways (Lilja et al., 2011), which subsequently leads to declined cognition.”
BackgroundSabbagh, M. N., Shah, F., Reid, R. T., Sue, L., Connor, D. J., Peterson, L. K. N., & Beach, T. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1771 · Cited by 57
α7 nAChR-mediated activation of MAP kinase pathways in PC12 cells
Gubbins, E. J., Gopalakrishnan, M., & Li, J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.083 · Cited by 57
Self-citationIkonomović, M. D., Mizukami, K., Warde, D., Sheffield, R., Hamilton, R. L., Wenthold, R. J., & Armstrong, D. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7196 · Cited by 57
Wang, Q., Wang, P. H., McLachlan, C. S., & Wong, P. T. ‐. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.016 · Cited by 51
Self-citationQuantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT
Oishi, N., Hashikawa, K., Yoshida, H., Ishizu, K., Ueda, M., Kawashima, H., Saji, H., & Fukuyama, H. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.02.014 · Cited by 49
Sharp, S. I., Ballard, C. G., Chen, C., & Francis, P. T. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000237065.78966.1b · Cited by 49
Ghahremani, M. H., Forget, C., & Albert, P. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1497-1506.2000 · Cited by 47
Wang, Q., Ting, W. L., Yang, H., & Wong, P. T. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706106 · Cited by 46
Self-citationCellular localization of adrenergic receptors in rat and human brain
Cash, R., Raisman‐Vozari, R., Lanfumey, L., Ploska, A., & Agid, Y. (1986) · Brain Research · doi:10.1016/0006-8993(86)91112-1 · Cited by 46
Effects of age and dopamine D2L receptor-deficiency on motor and learning functions
Fetsko, L. A., Xu, R., & Wang, Y. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.04.005 · Cited by 45
Analysis of NR3A receptor subunits in human native NMDA receptors
Nilsson, A., Eriksson, M., Muly, E. C., Åkesson, E., Samuelsson, E., Bogdanović, N., Benedikz, E., & Sundström, E. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.008 · Cited by 45
Li, Y., Huang, X., Deng, C., Meyer, B. J., Wu, A., Yu, Y., Ying, W., Yang, G., Yenari, M. A., & Wang, Q. (2009) · Synapse · doi:10.1002/syn.20722 · Cited by 45
Self-citationFaghih, R., Gfesser, G. A., & Gopalakrishnan, M. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907780832751 · Cited by 44
Chen, L., Wang, H., Zhang, Z., Li, Z., He, D., Sokabe, M., & Chen, L. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22345 · Cited by 44
Zhen, X., Zhang, J., Johnson, G., & Friedman, E. (2001) · PubMed · Cited by 43
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišťák, P., Ressner, P., et al. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00966.x · Cited by 43
Meana, J. J., Barturen, F., Garro, M. A., García‐Sevilla, J. A., Fontán, A., & Zarranz, J. J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10067.x · Cited by 43
Turle-Lorenzo, N., Maurin, B., Puma, C., Chezaubernard, C., Morain, P., Baunez, C., Nieoullon, A. L., & Amalric, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.109207 · Cited by 41
Visanji, N. P., Fox, S. H., Johnston, T. H., Millan, M. J., & Brotchie, J. M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144097 · Cited by 40
Costa-Aze, V. D. S., Duchatelle, P., Boulouard, M., & Dauphin, F. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.94 · Cited by 39
Soliakov, L. S., & Wonnacott, S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703873 · Cited by 39
Sawaguchi, T. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00044-4 · Cited by 39
Ward, R. J., Lallemand, F., Witte, P. D., & Dexter, D. T. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.003 · Cited by 38
Blundell, J. J., & Adamec, R. E. (2007) · Brain Research · doi:10.1016/j.brainres.2006.09.078 · Cited by 38
The dopaminergic basis of cognitive and motor performance in Alzheimer's disease
Reeves, S., Mehta, M. A., Howard, R. J., Grasby, P. M., & Brown, R. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.005 · Cited by 36
Zhen, X., Torres, C. A., Cai, G., & Friedman, E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.6.1356 · Cited by 36
Mitsis, E. M., Reech, K. M., Bois, F., Tamagnan, G. D., MacAvoy, M. G., Seibyl, J. P., Staley, J. K., & van Dyck, C. H. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064030 · Cited by 36
Pascual, J., Grijalba, B., Garcı́a-Sevilla, J. A., Zarranz, J. J., & Pazos, Á. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90614-d · Cited by 32
Piggott, M. A., Ballard, C. G., Dickinson, H. O., McKeith, I. G., Perry, R. H., & Perry, E. K. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570600647x · Cited by 31
Liu, H.-P., Lin, W.-Y., Liu, S.-H., Wang, W.-F., Tsai, C.-H., Wu, B.-T., Wang, C.-K., & Tsai, F.-J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000254757 · Cited by 29
Tsang, S. W. Y., Vinters, H. V., Cummings, J. L., Wong, P. T. ‐., Chen, C., & Lai, M. K. P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.014 · Cited by 29
Lai, M. K. P., Tsang, S. W., Francis, P. T., Esiri, M. M., Hope, T., Lai, O. –., Spence, I., & Chen, C. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0825-9 · Cited by 28
Sun, W., Sugiyama, K., Fang, X., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.048 · Cited by 26
Fang, X., Sugiyama, K., Akamine, S., & Namba, H. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.010 · Cited by 24
Mizukawa, K., McGeer, E. G., & McGeer, P. L. (1993) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160027 · Cited by 24
Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain
Wang, Q., Zengin, A., Ying, W., Newell, K. A., Wang, P., Yeo, W. W., Wong, P. T. ‐., Yenari, M. A., & Huang, X. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.026 · Cited by 23
Self-citationXiong, H., McCabe, L., Costello, J., Anderson, E., Weber, G. A., & Ikezu, T. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.007 · Cited by 21
N‐methyl‐D‐aspartate receptor and apoptosis in Alzheimer's disease and multiinfarct dementia
Fang, M., Li, J., Tiu, S. C., Zhang, L., Wang, M., & Yew, D. T. W. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20558 · Cited by 20
Self-citationBel, E. A. D., & Slater, P. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90340-y · Cited by 17
Adrenergic receptors on cerebral microvessels in control and Parkinsonian subjects
Cash, R., Lasbennes, F., Sercombe, R., Seylaz, J., & Agid, Y. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90465-5 · Cited by 14
The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease
Panegyres, P. K., Toufexis, K., & Kakulas, B. A. (2002) · Journal of Neural Transmission · doi:10.1007/s702-002-8238-9 · Cited by 14
Effects of Dopamine Agonists on Neuropsychiatric Symptoms of Parkinson’s Disease
Rektorová, I. (2010) · Neurodegenerative Diseases · doi:10.1159/000295665 · Cited by 14
Kalaria, R. N., Ac, A., & Harik, S. (1989) · PubMed · Cited by 13
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health
Parker, A., Fonseca, S., & Carding, S. R. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1638722 · Cited by 702
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Liu, P., Wu, L., Peng, G., Han, Y., Tang, R., Ge, J., Zhang, L., Jia, L., Yue, S., Zhou, K., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.05.008 · Cited by 669
“Abnormal 5-HT biosynthesis caused by intestinal dysbiosis may affect the pathological process of AD (Xu et al., 2012).”
Metadata
- Authors
- Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 97
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2085813915
- Cited by
- 301
- References
- 176
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.